Clinical trial
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant…
NCT00458952 · Molecular Insight Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00458952 |
|---|---|
| Title | Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma |
| Official title | A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma |
| Lead sponsor | Molecular Insight Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Pheochromocytoma, Paraganglioma |
| Intervention type | Drug |
| Interventions | Ultratrace Iobenguane (MIBG) I 131 |
| Enrollment | 24 |
| Start date | Apr 1, 2007 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2011 |
| First posted | Apr 11, 2007 |
| Last update posted | Jul 13, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: